Mutations in the NAD(P)H oxidase gene may be associated with abnormal superoxide generation, nitric oxide (NO) availability and cardiovascular diseases. We investigated the prevalence of the NAD(P)H oxidase p22phox gene C242T polymorphism, and its possible association with blood pressure, NO production, salt sensitivity and cardiovascular risk factors in Hispanics. Genotype frequencies were as follows: CC, 52.9%; CT, 40.3%; and TT, 6.8%. There were no significant differences in systolic blood pressure, diastolic blood pressure, age, weight, fasting and post-load glucose levels, LDL and HDL cholesterol, triglyceride and urinary albumin levels in subjects with CC, CT or the TT genotypes. Presence of the T allele was associated with increased salt sensitivity in women, but not in men.
Introduction
The superoxide-generating NAD(P)H is a multisubunit enzyme complex. One of its components, the p22phox is required for oxidase activity. 1 This enzyme complex plays a major role in superoxide ion production in blood vessels. [1] [2] [3] [4] Superoxide ions are known to avidly interact with nitric oxide (NO), reducing its bioactivity by generating peroxynitrite. [2] [3] [4] Increased activity of the NAD(P)H oxidase system is expected to be associated with reduced NO levels, vascular dysfunction, hypertension and salt sensitivity. [4] [5] [6] The latter, is known to be associated with reduced NO bioactivity [7] [8] [9] [10] [11] [12] [13] and increased superoxide production. 5, 6 Consequently, genetic and/or disease-induced changes in NADPH oxidase activity and superoxide formation may play an important role in the pathogenesis of saltsensitive hypertension.
CYBA is the gene that encodes the essential subunit of the NAD(P)H oxidase p22phox.
14 Several polymorphisms have been identified in the promoter and in the coding region of this gene. Among them, the C242T polymorphism has been reported to be associated with increase NAD(P)H oxidase activity and cardiovascular diseases. 15, 16 Because changes in NAD(P)H-dependent superoxide production could affect NO bioactivity and thus the blood pressure (BP) response to salt intake, we investigated the effects of the C242T mutation in the NAD(P)H oxidase p22phox gene on salt sensitivity. In addition, the impact of the mutation on NO metabolite levels and cardiovascular risk factors was evaluated. Further, the prevalence of this polymorphism in Venezuelans, a previously nonstudied ethnic group, was investigated.
Materials and methods

Study population
A total of 119 consecutive, otherwise healthy subjects, attending our Center for the Detection and Treatment of Silent Cardiovascular Risk Factors were evaluated for NAD(P)H oxidase p22phox gene C242T polymorphism, glucose tolerance testing, salt sensitivity, NO metabolite excretion and cardiovascular risk factors. The exclusion criteria were age greater than 70, a history of angina pectoris, myocardial infarction, congestive heart failure, valvular heart disease, cerebral infarction or haemorrhage, transient ischaemic attacks, arteriosclerosis obliterans, pulmonary disease; any patient with active disease, evidences of renal or hepatic dysfunction, urinary tract infection, active inflammatory disease states, systolic blood pressure (SBP) 4170 mm Hg or diastolic blood pressure (DBP) 4110 mm Hg, diabetes mellitus; treatment with organic nitrates, women on birth control pills, and serum creatinine concentration greater than 2 mg/dl. A complete medical history, physical examination and laboratory work-up, which included a complete haematology, blood chemistry, lipid panel, oral glucose tolerance test, liver function tests and urinalysis, were obtained. Oral glucose tolerance was determined by determining glucose and insulin levels before (12 h fasting) and after (30, 60, 90, 120 and 180 min) the oral intake of 75 g of glucose. All medications including vitamins were discontinued for 4 weeks and antihypertensive medications for 8 weeks before entering the study. The research protocol was approved by the Central University Hospital of the city of Caracas, Venezuela, and by the Nova Southeastern University Review Boards. All participants gave written informed consent.
Determination of salt sensitivity Salt sensitivity testing was determined as previously described. 13 Briefly, subjects were placed on a high salt intake for 7 days, followed by a low salt intake for an additional 7 days. On day 6 or 7 of both sodium diets, patients returned to the Center for the following procedures: SBP, DBP, 24 h sodium and potassium excretion, 24 h nitrites and nitrates excretion, serum and urinary creatinine levels. The average of three BP determinations in supine position was used for determining salt sensitivity. Patients were classified as salt sensitive, salt intermediate and salt resistant. If the difference in mean BP between high-and low-sodium weeks was equal to or more than 10 mm Hg, the patient was deemed salt sensitive. Salt resistance was defined as increases of less than 3 mm Hg, no change or decreases in mean BP. Subjects with BP increases greater than three but less than 10 mm Hg were classified as of intermediate sensitivity to salt.
Genetic analysis: NAD(P)H oxidase p22phox gene C242T polymorphism DNA was extracted from blood anticoagulated with ethylenediaminetetraacetic acid according to standard protocols. The p22phox gene containing this polymorphic site was amplified by polymerase chain reaction (PCR) (Promega-PCR Core System II). The PCR was carried out in a volume of 25 ml containing 2.5 ml of DNA, and amplified with 1 mM of each primer (forward 5 0 -TGCTTGTGGGTAAACC AAGG-3 0 ; reverse 5 0 -GGAAAAACACTGAGGTAAG TG-3 0 ). Because the C-T mutation of the C242T polymorphic site produces the RsaI digestion site, RsaI restriction fragment length polymorphism (RFLP) was used to analyse the polymorphism of the p22phox gene. After digestion with RsaI (New England Biolabs, Ipswich, MA, USA), the samples were separated on 3% agarose gel and visualized with ethidium bromide. Digestion of the PCR products yielded bands of 348 bp in CC homozygotes, 188 and 160 bp in TT homozygotes and all three bands in heterozygotes. Each genotype was read by two individuals independently; if in conflict, genotyping was repeated.
Determination of nitrites and nitrates in urine samples
Nitrites plus nitrates were quantified employing a modification of a commercially available NO assay kit (Oxford Biomedical Research Inc., Oxford, MI, USA). 13 Twenty-four-hour urine samples were collected at the end of the high-and low-sodium diets (10 days restriction from nitrate-and nitrite-containing foods). Nitrates present in the urine supernatant were reduced 1:1 to nitrites by incubation with metallic cadmium beads for 24 h. The total nitrite concentration was then estimated by the Griess reaction, using a multiwell microplate for reading of sample absorbance at 540 nm. This value represents the total amount of urine NO end products (nitrite þ nitrate). Urine samples were processed in duplicate. 
Statistics and data analysis
Results
A total of 119 subjects were studied. The characteristics of the subjects are shown in Table 1 . The frequency of the C and T alleles was 73 and 27%, respectively. Genotype frequencies were as follows: CC, 52.9%; CT, 40.3%; and TT, 6.8% (Table 1 ). The sample examined was in Hardy-Weinberg equilibrium. No significant differences were found in the age, weight, waist-to-hip ratio, BMI, SBP, DBP, pulse pressure, heart rate, fasting and post-load serum glucose and insulin, LDL and HDL cholesterol, triglycerides and urinary albumin excretion levels of subjects with and without the mutation (Table 1 ). In addition, the percentage of subjects with hypertension (X140/90 mm Hg) was comparable among the three groups: 9.5% in CC, 10.1% in CT and 12.5% in subjects with the TT genotype.
The relationships between salt sensitivity and the C242T polymorphism were assessed ( Figure 1 ). Lowering salt intake from 18 to 2.4 g/day reduced BP in all groups of subjects; however, there was a trend for greater BP reduction (5.171 in CC, 7.57 1.5 in CT and 7.871.9 mm Hg in TT) in subjects carrying the T allele. Although there were no gender differences in the frequency of the T allele (31.5% in men and 30.8% in women), women carrying the T allele were more salt sensitive than those without it (Po0.01). In men, the T allele was not a determinant of salt sensitivity (P40.5) (Figure 1b) . The possible existence of confounding factors, such as hyperinsulinaemia, obesity and hypertension, in determining the increase in salt sensitivity observed in women with the T allele was investigated. No significant differences in body weight, BMI, waistto-hip ratio (WHR), BP and fasting and post-load glucose and insulin levels were observed between women with the CC and the CT genotypes, or between men with the CC and the CT genotypes ( Table 2) .
The impact of menopause on salt sensitivity associated with the T allele was also investigated. Salt restriction lowered SBP by 371 in pre-menopausal women and by 6.271.3 mm Hg in post-menopausal women with the CC genotype. In pre-and post-menopausal women carrying the T allele, salt restriction lowered SBP by 7.772.2 and 13.67 3 mm Hg, respectively. However, for both groups, pre-menopausal women were on average 20 years younger and had SBP that was 15 mm Hg lower than post-menopausal women.
The effects of changes in dietary salt intake on urinary sodium excretion are shown in Table 3 . The Abbreviations: AUC glucose, area under the curve of glucose levels after a 75-g oral load of glucose; AUC insulin, area under the curve of insulin levels after a 75-g oral load of glucose; BMI, body mass index; DBP, diastolic blood pressure; FSG, fasting serum glucose; FSI, fasting serum insulin; HDL-C, high-density lipoprotein cholesterol; HR, heart rate; LDL-C, low-density lipoprotein cholesterol; SBP: systolic blood pressure; TG, triglyceride in mg/dl; UAE, urinary albumin excretion; WHR, waist-to-hip ratio. With the exception of the group prevalence, there were no significant differences for all variables between the three groups. presence of the T allele did not affect the urinary excretion of sodium at three different levels of salt intake. The 24-h urinary sodium excretion was higher in men than in women (Po0.01). The possibility that abnormal sodium handling could be responsible for the increase in salt sensitivity in women with the CT þ TT genotypes was investigated (Table 3) . However, women with the CC or the CT þ TT genotypes excreted comparable amounts of sodium (P40.1). Similar results were observed in men.
Urinary excretion of NO metabolites was quantified at three different levels of salt intake (Figure 2) . At usual free-salt diet (14174 mEq of sodium/day), urinary NO metabolites excretion averaged 9307 82 mmol/day. For the study population, no significant difference in the excretion of NO metabolites was found between subjects carrying the CC and the CT genotypes (P40.1) (Figure 2) . However, the TT genotype was associated with a significant reduction in the 24 h excretion of nitrates þ nitrites (Po0.05). Urinary NO metabolite excretion was greater in men than in women (Po0.01) (Figure 3) . For either gender, comparable NO metabolite excretion levels were found in subjects with the CC and CT genotypes. In addition, men (n ¼ 5) and women (n ¼ 3) carrying the TT genotype excreted lower amounts of NO metabolites than those with the CT or CC genotypes, respectively (Figure 3 ). Abbreviations: AUC glucose, area under the curve of glucose levels after a 75-g oral load of glucose; AUC insulin, area under the curve of insulin levels after a 75-g oral load of glucose; BMI, body mass index; DBP, diastolic blood pressure; FSG, fasting serum glucose; FSI, fasting serum insulin; HDL-C, high-density lipoprotein cholesterol; HR, heart rate; HT, hypertension; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TG, triglyceride in mg/dl; UAE, urinary albumin excretion; WHR, waist-to-hip ratio. There were no significant differences for all variables between CC and CT+TT subjects, both for women or men. Shown are means7s.e.m. for the urinary sodium excretion in mEq/day during usual sodium intake, high-sodium diet and low-sodium diets, in men and women with and without the C242T polymorphism. Values in women were significantly different from values in men at *Po0.05 and **Po0.01. No significant differences were found between CC and CT+TT subjects at any of the three levels of salt intake. 
Discussion
Ethnicity and NAD(P)H oxidase p22phox gene C242T polymorphism In addition to disease states, the prevalence of a specific genetic polymorphism is determined by ethnicity. The prevalence of NAD(P)H p22phox C242T gene polymorphism has been established for Caucasians, Japanese and Chinese populations. However, such information was not available for Hispanics. The frequency of the T allele described for healthy subjects is less common in Japanese (0.07-0.13) and Chinese (0.066) than in European and Australian Caucasians (0.23-0.31). [17] [18] [19] [20] [21] [22] The frequency of the T allele in Venezuelans reported in this study was comparable to that previously described for Caucasians, as the T allele was found in 27% of the Venezuelan subjects studied (present study). These findings are consistent with previous observations, where the frequency of both the alpha adducin and the eNOS polymorphisms described for Venezuelans was comparable to that of Anglo-Saxons and Spanish Caucasians, and significantly different from that of Orientals and African-Americans. 11, 12 These findings support the European ancestry of the Venezuelan population studied, and further stress the role of ethnicity in determining the prevalence of gene polymorphisms. In addition, and as expected, our results indicate that the prevalence of the NAD(P)H oxidase p22phox gene C242T polymorphism is comparable in women and men.
NAD(P)H polymorphisms, cardiovascular risk factors and cardiovascular diseases
The role of NADPH oxidase and its different subunits in hypertension has been investigated. Increases in mRNA and protein expression of NADPH subunits in the renal vasculature, macula densa and the distal nephron have been observed in spontaneously hypertensive rats preceding the development of hypertension. 23 These findings suggest that at least in this animal model of hypertension, the increase in NADPH oxidase may lead to renal dysfunction. 23 Therefore, the clinical impact of the NAD(P)H p22phox gene polymorphism would depend on the extent at which the mutation affects NADPH oxidase activity. However, very few studies have actually evaluated the physiological consequences of the mutation. In one study, saphenous veins obtained from individuals with the CT/TT genotypes were reported to produce less superoxide ions than veins of subjects with the CC genotype. 24 In addition, the CT/TT genotypes were associated with increased endothelium-mediated dilation of epicardial arteries. 15 Both studies suggested that the T allele might exert cardiovascular protection. However, clinical studies searching for the association of the polymorphism with cardiovascular diseases have provided contradictory results. Although the T allele appeared to confer cardiovascular risk protection in some studies, 16, 17, 20, [25] [26] [27] either no protection or increase risk was found in others. 15, 17, 21, 22 In fact, the C242T polymorphism was found associated with coronary artery spasm, 15 coronary artery disease, 21 cerebrovascular disease and with atherothrombotic infarction. 17, 22 In addition, in this work, we did not observe an association between NAD(P)H oxidase p22phox gene C242T polymorphism and cardiovascular risk factors (obesity, BP, hypertension, dyslipidaemia, hyperglycaemia, hyperinsulinaemia and urinary albumin levels) in an otherwise healthy young adult population. However, these controversial results may result from possible linkage disequilibrium between this single nucleotide polymorphism and other functional polymorphisms within the candidate gene. Further studies are required to solve this. In summary, and based on the available information, our findings suggest that in Hispanics the C242T polymorphism is not associated with cardiovascular risk factors, and may not predispose to cardiovascular events. NAD(P)H polymorphisms, salt sensitivity and NO Salt sensitivity is characterized by a substantial increase in BP induced by salt loading and/or by a significant reduction in BP following a period of salt restriction. 13, 28 Although the exact cause of salt sensitivity remains unknown, both genetic and environmental factors seem to interact in determining the BP response to changes in salt intake. 11, 12, [29] [30] [31] [32] [33] Establishing the genes involved in the BP reactivity to salt would help in identifying patients who would benefit from salt restriction, as well as in preventing salt-sensitive hypertension, a condition known to be associated with increased risk for cardiovascular events. [34] [35] [36] [37] [38] In this study, we demonstrated that women with the T allele were more salt sensitive than those without the polymorphism. Interestingly, such an association was not found in men. Insulin resistance, older age, hormonal state, African-American ethnicity and hypertension are known to be associated with salt sensitivity. [11] [12] [13] 27, 32, 39, 40 However, women with and without the T allele had comparable ages, ethnic origins, BP, BMI, body weights, WHR and fasting and post-load glucose and insulin levels. Further, we found that women with and without the T allele excreted comparable amounts of sodium when exposed to a high-or to a low-salt diet. Therefore, it is unlikely that the abovedescribed factors contribute to the increase in salt sensitivity observed in women carrying the T allele. The mechanisms responsible for the gender differences in BP control and regulation are not clear. The BP sensitivity to salt of women is known to be low in pre-menopausal women, and it increases after menopause. 39 Although this pattern may be owing to aging and increase in BP, it may also be related to the modification of the sex hormone profile. In our study, post-menopausal women had higher BP, were more salt sensitive and obviously older (20 years on average) than pre-menopausal women. However, both pre-and post-menopausal women carrying the T allele were more salt sensitive than their counterparts with the CC genotype. Therefore, our results suggest that the presence of the T allele or the lack of the protection conferred by the C allele, and not the hormonal status, is what seems to determine the increase in salt sensitivity observed in women.
Impaired NO bioactivity has also been associated with salt sensitivity. [7] [8] [9] [10] [11] [12] [13] 38 Reduced NO levels may result from decreased production as well as from increased inactivation. Superoxide ions are known to reduce NO bioavailability. 41 It is possible that genetically determined changes in NAD(P)H activity affecting superoxide formation may change NO bioactivity, and thus the subject's salt sensitivity. Assessing NO bioactivity in humans is limited by the unavailability of specific and sensitive noninvasive assays for quantifying NO levels. Being aware of this limitation but in the absence of better methodologies, 24-h urinary levels of nitrates þ nitrites were employed to assess the impact of the p22phox C242T gene polymorphism on NO levels. As described above, women carrying the mutation (CT) had increased salt sensitivity; however, their NO metabolite excretion was not different from that of women with the wild genotype (CC). Therefore, and at least for this polymorphism, NO metabolite excretion was not directly associated with salt sensitivity. In addition, our results argue against the view that the presence of T allele increases NO bioactivity. 15, 24 Despite there were few subjects homozygous for the T allele, the results obtained in these individuals deserve additional discussion. Interestingly, men and women homozygous for the T allele (TT) excreted lower amounts of NO metabolites than men and women carrying the CC or CT genotypes. The observation that both T alleles must be present to observe a reduction in NO levels suggests that the C allele protects against the inhibition of NO metabolism associated with the T allele. In conclusion, and as long as the urinary excretion of nitrates þ nitrites reflects changes in NO metabolism, our results suggest that the p22phox gene plays a role in the genetic control of NO levels.
In summary, the prevalence of the NAD(P)H oxidase p22phox gene C242T polymorphism in otherwise healthy Venezuelans is comparable to that reported for Caucasians. The T allele was not associated with cardiovascular risk factors, abnormal sodium excretion, hyperinsulinaemia or hypertension. However, in women, the T allele appeared to be a genetic susceptibility factor for salt sensitivity. Both in women and men, the p22phox gene may play a role in the genetic control of NO levels.
What is known on this topic?
K Salt-sensitive hypertension seems to be determined by the interplay of genetic and environmental factors. Impaired NO bioactivity has been associated with salt-sensitive hypertension.
5-10
K NAD(P)H oxidase plays a major role on superoxide production in blood vessels. Superoxide ions avidly react with NO to reduce its bioactivity and generate peroxynitrite. High salt intake increases NADP(P)H-mediated superoxide production in salt-sensitive rats.
2-4 12, 13
K Mutations in the NAD(P)H gene (C242T) may be associated with changes in NO availability, with alterations in the BP reactivity to salt, and with increased risk for cardiovascular events. K No previous studies have investigated the relationships between the C242T polymorphism, salt sensitivity and NO metabolite excretion.
What this study adds:
K This is the first study on the prevalence of the C242T polymorphism in Hispanics, which in addition evaluates its association with salt sensitivity, NO production and cardiovascular risk factors. K Genotype frequencies for Hispanics were comparable to those reported for Caucasians. K In women, but not in men, the C242T polymorphism was associated with the increase in salt sensitivity, which was independent of obesity, insulin, glucose and BP levels. K No association between the C242T polymorphism, sodium excretion, insulin resistance and cardiovascular risk factors was found. K Subjects homozygous for the T allele had reduced excretion of NO metabolites. Women carrying the TT genotype excreted the lowest amounts of NO metabolites. Presence of the C allele seems to protect against low NO metabolite levels observed in subjects homozygous to the T allele. K In women, the p22phox gene may be a genetic susceptibility factor for the BP response to salt intake. K The p22phox gene may play a role in the genetic control of NO levels.
